RUA Life Sciences plc (AIM:RUA)
London · Delayed Price · Currency is GBP · Price in GBX 11.75
0.00 (0.00%)
Jul 28, 2025, 12:47 PM GMT+1
RUA Life Sciences Revenue
In the fiscal year ending March 31, 2025, RUA Life Sciences had annual revenue of 4.11M GBP with 87.72% growth. RUA Life Sciences had revenue of 2.59M in the half year ending March 31, 2025, with 140.84% growth.
Revenue
4.11M
Revenue Growth
+87.72%
P/S Ratio
1.77
Revenue / Employee
102.83K
Employees
40
Market Cap
7.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.11M | 1.92M | 87.72% |
| Mar 31, 2024 | 2.19M | 12.00K | 0.55% |
| Mar 31, 2023 | 2.18M | 554.00K | 34.09% |
| Mar 31, 2022 | 1.63M | 97.00K | 6.35% |
| Mar 31, 2021 | 1.53M | 1.04M | 212.47% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |